ARDX:NSD-Ardelyx Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.82

Change

+0.03 (+1.68)%

Market Cap

USD 0.34B

Volume

3.57M

Avg Analyst Target

USD 9.00 (+394.51%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


ARDX Stock Forecast & Price:
Based on the Ardelyx Inc stock forecasts from 2 analysts, the average analyst target price for Ardelyx Inc is USD 9.00 over the next 12 months. Ardelyx Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ardelyx Inc is Very Bearish, which is based on 0 positive signals and 4 negative signals. At the last closing, Ardelyx Inc’s stock price was USD 1.82. Ardelyx Inc’s stock price has changed by +4.00% over the past week, +40.00% over the past month and +30.00% over the last year.

About Ardelyx Inc (ARDX:NSD)

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III cli ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-12-08 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
REGN Regeneron Pharmaceuticals Inc

+1.15 (+0.15%)

USD81.40B 15.14 12.35
VRTX Vertex Pharmaceuticals Inc

+3.74 (+1.18%)

USD80.04B 24.25 17.39
MRNA Moderna Inc

+5.70 (+3.18%)

USD67.59B 6.10 4.60
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+9.18 (+5.64%)

USD39.94B 3.92 1.87
GMAB Genmab AS

+0.12 (+0.26%)

USD29.93B 36.52 3.71
ALNY Alnylam Pharmaceuticals Inc

+6.68 (+2.89%)

USD28.46B N/A -29.83
SGEN Seagen Inc

+5.88 (+4.93%)

USD22.16B 55.02 -38.32
ARGX argenx NV ADR

+5.15 (+1.34%)

USD21.93B N/A -22.20
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing ARDX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 65.45% 96% A 98% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 65.45% 96% A 98% A+
Trailing 12 Months  
Capital Gain 15.19% 89% B+ 92% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 15.19% 89% B+ 92% A-
Trailing 5 Years  
Capital Gain -70.16% 47% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -70.16% 47% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain 6.03% 71% C- 69% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 6.03% 71% C- 66% D
Risk Return Profile  
Volatility (Standard Deviation) 92.84% 20% F 12% F
Risk Adjusted Return 6.49% 68% D+ 51% F
Market Capitalization 0.34B 67% D+ 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.19 21% F 17% F
Price / Cash Flow Ratio -2.20 47% F 56% F
EV/EBITDA -2.67 69% D+ 69% D+
Management Effectiveness  
Return on Equity -153.93% 19% F 11% F
Return on Invested Capital -105.80% 20% F 13% F
Return on Assets -45.47% 21% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 1.71 71% C- 61% D-
Short Percent 4.62% 40% F 32% F
Beta 1.47 29% F 23% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.